{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:14:02Z","timestamp":1783779242011,"version":"3.55.0"},"posted":{"date-parts":[[2026,6,11]]},"group-title":"Pathology","reference-count":44,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  In clinical trials for ulcerative colitis (UC), pathologists assess disease severity through standardized histological indices, including the Geboes Score, Robarts Histopathology Index (RHI), and Nancy Histologic Index (NHI). Despite strong associations with clinical outcomes, histologic scoring suffers from inter- and intra-reader variability, and consensus criteria for histologic remission remain uncertain. Through a consortium approach, we developed an artificial intelligence-based measurement (AIM) tool for scoring histology in UC mucosal biopsies (AIM-HI UC). This model, trained on a large dataset of UC biopsies (N=10,230), utilizes additive multiple instance learning models leveraging PLUTO, a pathology foundation model, that predict each of the Geboes subgrades, from which the Geboes grade-level score, RHI, and NHI can be calculated. Evaluation of this model on a standalone verification set including clinical trial specimens established algorithm non-inferiority and\/or superiority relative to standard qualified pathologists through comparison of algorithm-consensus and pathologist-consensus agreement metrics (non-inferior if difference &gt;-0.1, superior if difference &gt;0, inclusive of confidence intervals). AIM-HI UC was determined to be non-inferior to pathologists (N=3) for the prediction of all seven Geboes subgrades, grade-level Geboes, RHI, NHI, histologic improvement (GS\n                  <jats:underline>&lt;<\/jats:underline>\n                  3.1), 2A histologic remission (GS&lt;2A.0), and 2B histologic remission (GS&lt;2B.0). AIM-HI UC was superior to pathologists for several Geboes subgrades (GS 0, GS 1, GS 2B, and GS 5), as well as grade-level Geboes, RHI, and positive percent agreement of 2A histologic remission. The model was shown to be greater than 99% repeatable for all histologic scoring metrics examined. Model-derived scores were shown to strongly correlate with canonical histologic features of inflammation, including the proportion of total epithelium that is inflamed (Spearman r=0.83; p&lt;0.01), the proportion of neutrophils localized within crypt epithelium (Spearman r=0.83, p&lt;0.01), and the amount of mucosal area classified as erosion or ulceration (Spearman r=0.80, p&lt;0.01). Overall, these results suggest that AIM-HI UC has the potential to improve consistency of UC histology interpretation, providing a path toward standardization of UC histology scoring in clinical trials.\n                <\/jats:p>","DOI":"10.64898\/2026.06.09.26355212","type":"posted-content","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:12Z","timestamp":1781222412000},"source":"Crossref","is-referenced-by-count":0,"title":["Standardized, repeatable ulcerative colitis histology scoring and endpoint assessment using an automated, foundation model-based tool"],"prefix":"10.64898","author":[{"given":"Waleed","family":"Tahir","sequence":"first","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Shamshoian","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Tauber","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani K.","family":"Clinton","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Griffin","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Shah","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetika","family":"Singh","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Fahy","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Sucipto","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A.","family":"Brosnan-Cashman","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara A.","family":"Altepeter","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"AbbVie Bay Area, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Crandall","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Duan","sequence":"additional","affiliation":[{"name":"Pfizer Research Technology Center, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Gale","sequence":"additional","affiliation":[{"name":"Pfizer Research Technology Center, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Gupta","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America Inc, Cambridge, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Haarmann","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Opfikon, ZH, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Harpaz","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Hooper","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Hurtado-Lorenzo","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Foundation, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader E.","family":"Hussaini","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America Inc, Cambridge, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Western University Faculty of Health Sciences, London, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Jones","sequence":"additional","affiliation":[{"name":"Foundation for the National Institutes of Health, North Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Kostiuk","sequence":"additional","affiliation":[{"name":"Crohn\u2019s and Colitis Foundation, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Laroux","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Lissoos","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell B.","family":"McBride","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedaa","family":"Najdawi","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Nayyar","sequence":"additional","affiliation":[{"name":"US Food and Drug Administration, Silver Spring, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Osterman","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Panchal","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America Inc, Cambridge, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-2313","authenticated-orcid":false,"given":"Darren","family":"Ruane","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paresh","family":"Thakker","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America Inc, Cambridge, MA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Travis","sequence":"additional","affiliation":[{"name":"University of Oxford Nuffield Department of Medicine, Oxford, England, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Wilson","sequence":"additional","affiliation":[{"name":"Kenneth Rainin Foundation, Oakland, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Jayson","sequence":"additional","affiliation":[{"name":"PathAI Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026071106550581000_2026.06.09.26355212v2.1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2026071106550581000_2026.06.09.26355212v2.2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab050"},{"key":"2026071106550581000_2026.06.09.26355212v2.3","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.233"},{"key":"2026071106550581000_2026.06.09.26355212v2.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.001"},{"key":"2026071106550581000_2026.06.09.26355212v2.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.11.010"},{"key":"2026071106550581000_2026.06.09.26355212v2.6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5217\/ir.2018.16.1.55","article-title":"Association of endoscopic and histological remission with clinical course in patients of ulcerative colitis","volume":"16","year":"2018","journal-title":"Intest Res"},{"key":"2026071106550581000_2026.06.09.26355212v2.7","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.2.174"},{"key":"2026071106550581000_2026.06.09.26355212v2.8","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.301"},{"key":"2026071106550581000_2026.06.09.26355212v2.9","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.20912"},{"key":"2026071106550581000_2026.06.09.26355212v2.10","doi-asserted-by":"publisher","DOI":"10.1007\/DCR.0b013e31819ad456"},{"key":"2026071106550581000_2026.06.09.26355212v2.11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.038"},{"key":"2026071106550581000_2026.06.09.26355212v2.12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309598"},{"key":"2026071106550581000_2026.06.09.26355212v2.13","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2020.06.043","article-title":"Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis","volume":"159","year":"2020","journal-title":"Gastroenterology"},{"key":"2026071106550581000_2026.06.09.26355212v2.14","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.cgh.2020.09.046","article-title":"Treat to target: The role of histologic healing in inflammatory bowel diseases: A systematic review and meta-analysis","volume":"19","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026071106550581000_2026.06.09.26355212v2.15","doi-asserted-by":"crossref","first-page":"e796","DOI":"10.1097\/MEG.0000000000002258","article-title":"Histological inflammatory activity can predict endoscopic relapse in patients with ulcerative colitis who have achieved mucosal healing","volume":"33","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026071106550581000_2026.06.09.26355212v2.16","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13375"},{"key":"2026071106550581000_2026.06.09.26355212v2.17","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.cgh.2019.09.021","article-title":"Discordance between patient-reported outcomes and mucosal inflammation in patients with mild to moderate ulcerative colitis","volume":"18","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026071106550581000_2026.06.09.26355212v2.18","unstructured":"Center for Drug Evaluation, Research. Ulcerative colitis: Developing Drugs for Treatment. U.S. Food and Drug Administration. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/ulcerative-colitis-developing-drugs-treatment (accessed 4 February 2026)"},{"key":"2026071106550581000_2026.06.09.26355212v2.19","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.404"},{"key":"2026071106550581000_2026.06.09.26355212v2.20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310393"},{"key":"2026071106550581000_2026.06.09.26355212v2.21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310187"},{"key":"2026071106550581000_2026.06.09.26355212v2.22","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.cgh.2018.10.032","article-title":"Comparison of the EMA and FDA guidelines on ulcerative colitis drug development","volume":"17","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026071106550581000_2026.06.09.26355212v2.23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-316702"},{"key":"2026071106550581000_2026.06.09.26355212v2.24","doi-asserted-by":"crossref","first-page":"100124","DOI":"10.1016\/j.modpat.2023.100124","article-title":"Artificial Intelligence Enables Quantitative Assessment of Ulcerative Colitis Histology","volume":"36","year":"2023","journal-title":"Mod Pathol"},{"key":"2026071106550581000_2026.06.09.26355212v2.25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/ueg2.12562","article-title":"An artificial intelligence-driven scoring system to measure histological disease activity in ulcerative colitis","volume":"12","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"2026071106550581000_2026.06.09.26355212v2.26","unstructured":"Bommasani R , Hudson DA , Adeli E , et al. On the opportunities and risks of foundation models. arXiv [cs.LG]. 2021."},{"key":"2026071106550581000_2026.06.09.26355212v2.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02857-3"},{"key":"2026071106550581000_2026.06.09.26355212v2.28","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: Results from a randomized, phase 2b study","volume":"21","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026071106550581000_2026.06.09.26355212v2.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.06.011"},{"key":"2026071106550581000_2026.06.09.26355212v2.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"2026071106550581000_2026.06.09.26355212v2.31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.033"},{"key":"2026071106550581000_2026.06.09.26355212v2.32","doi-asserted-by":"crossref","unstructured":"Javed SA , Juyal D , Padigela H , et al. Additive MIL: Intrinsically Interpretable Multiple Instance Learning for Pathology. In: Koyejo S , Mohamed S , Agarwal A , et al., eds. Advances in Neural Information Processing Systems. Curran Associates, Inc. 2022:20689\u2013702.","DOI":"10.52202\/068431-1504"},{"key":"2026071106550581000_2026.06.09.26355212v2.33","unstructured":"Juyal D , Padigela H , Shah C , et al. PLUTO: Pathology-Universal Transformer. arXiv [eess.IV]. 2024."},{"key":"2026071106550581000_2026.06.09.26355212v2.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21896-9"},{"key":"2026071106550581000_2026.06.09.26355212v2.35","unstructured":"Gerardin Y , Shamshoian J , Shen J , et al. Improved statistical benchmarking of digital pathology models using pairwise frames evaluation. arXiv [cs.CV]. 2023."},{"key":"2026071106550581000_2026.06.09.26355212v2.36","doi-asserted-by":"crossref","first-page":"e0248224","DOI":"10.1371\/journal.pone.0248224","article-title":"Real-life evaluation of histologic scores for Ulcerative Colitis in remission","volume":"16","year":"2021","journal-title":"PLoS One"},{"key":"2026071106550581000_2026.06.09.26355212v2.37","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAD142"},{"key":"2026071106550581000_2026.06.09.26355212v2.38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: a pivotal role in health, inflammation, and cancer","volume":"10","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026071106550581000_2026.06.09.26355212v2.39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.31662\/jmaj.2024-0206","article-title":"Pathology foundation models","volume":"8","year":"2025","journal-title":"JMA J"},{"key":"2026071106550581000_2026.06.09.26355212v2.40","doi-asserted-by":"crossref","unstructured":"Breen J , Allen K , Zucker K , et al. A comprehensive evaluation of histopathology foundation models for ovarian cancer subtype classification. arXiv [eess.IV]. 2024.","DOI":"10.1038\/s41698-025-00799-8"},{"key":"2026071106550581000_2026.06.09.26355212v2.41","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1038\/s41467-025-58796-1","article-title":"A clinical benchmark of public self-supervised pathology foundation models","volume":"16","year":"2025","journal-title":"Nat Commun"},{"key":"2026071106550581000_2026.06.09.26355212v2.42","doi-asserted-by":"crossref","unstructured":"Altepeter TA , Bhattacharya S , Brosnan-Cashman J , et al. Su1904: CONSORTIUM-DRIVEN DEVELOPMENT OF PATHOLOGY FOUNDATION MODEL-BASED APPROACHES FOR AUTOMATED SCORING OF HISTOPATHOLOGY IN ULCERATIVE COLITIS. Gastroenterology. 2025;169:S \u2013 882.","DOI":"10.1016\/S0016-5085(25)02965-8"},{"key":"2026071106550581000_2026.06.09.26355212v2.43","first-page":"848344","article-title":"The role and function of mucins and its relationship to inflammatory bowel disease","volume":"9","year":"2022","journal-title":"Front Med (Lausanne"},{"key":"2026071106550581000_2026.06.09.26355212v2.44","doi-asserted-by":"crossref","first-page":"102527","DOI":"10.1016\/j.xcrm.2025.102527","article-title":"Contrastive learning enhances fairness in pathology artificial intelligence systems","volume":"6","year":"2025","journal-title":"Cell Rep Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.09.26355212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T13:55:15Z","timestamp":1783778115000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.06.09.26355212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":44,"URL":"https:\/\/doi.org\/10.64898\/2026.06.09.26355212","relation":{},"subject":[],"published":{"date-parts":[[2026,6,11]]},"subtype":"preprint"}}